IVEVF (Inventiva) 10-Year Share Buyback Ratio: -25.30% (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

IVEVF Inventiva SA IVEVF
35 GF Score
Price $3.59
GF Value $0.21
! 7 Warning Signs
View Full Analysis

What is Inventiva 10-Year Share Buyback Ratio?

Inventiva IVEVF 35 10-Year Share Buyback Ratio is -25.30 as of Dec. 2025. GuruFocus rates IVEVF with a GF Score™ of 35/100 and a GF Value™ of $0.21. The stock has 7 warning signs investors should review. Among 667 Biotechnology companies, Inventiva ranks worse than 71.81% on this metric.

Shares Outstanding (EOP) are shares that have been authorized, issued, and purchased by investors and are held by them.

10-Year Share Buyback Ratio measures the average annual proportion of a company's outstanding shares repurchased over the past ten years. It is calculated as the annualized percentage change in shares outstanding from ten years ago to the current year. A positive ratio may indicate share buybacks over the period, while a zero or negative ratio may reflect no repurchases or potential share issuance. Inventiva's current 10-Year Share Buyback Ratio was -25.30%.

IVEVF's 10-Year Share Buyback Ratio is ranked worse than
71.81% of 667 companies
in the Biotechnology industry
Industry Median: -11.7 vs IVEVF: -25.30

Inventiva (OTCPK:IVEVF) 10-Year Share Buyback Ratio Explanation

A negative number means the company might be issuing new shares. A positive number indicates that the company is buying back shares.


Be Aware

Investors usually like share buybacks. But as pointed by Warren Buffett, only if a company buys back shares at the prices below the stock's intrinsic value, it rewards remaining shareholders. If a company buys its overvalued stocks back, it destroys shareholder value.


Inventiva 10-Year Share Buyback Ratio Related Terms


IVEVF vs VRTX, REGN, RVMD: 10-Year Share Buyback Ratio Comparison

For the Biotechnology subindustry, Inventiva's 10-Year Share Buyback Ratio, along with its competitors' market caps and 10-Year Share Buyback Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Inventiva 10-Year Share Buyback Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Inventiva's 10-Year Share Buyback Ratio distribution charts can be found below:

* The bar in red indicates where Inventiva's 10-Year Share Buyback Ratio falls into.


IVEVF
35GF Score
Inventiva SA IVEVF
10-Year Share Buyback Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Inventiva 10-Year Share Buyback Ratio Calculation

This is the annualized percentage change in shares outstanding from ten years ago to the current year. The annualized percentage change is calculated with least-square regression based on the eleven years of annual data on Shares Outstanding (EOP).

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average dividends per share growth rate.

What does a 10-Year Share Buyback Ratio of -25.30 mean?
Inventiva (IVEVF) has a 10-Year Share Buyback Ratio of -25.30 as of Dec. 2025. The 10-Year Share Buyback Ratio measures the average annual proportion of a company's outstanding shares repurchased over the past ten years. It is calculated as the annualized percentage change in shares outstanding from ten years ago to the current year. View historical data for Inventiva and its competitors. According to the industry distribution chart, Inventiva ranks #479 out of 667 companies in the Biotechnology industry, placing it in the top 71.8%.
Is Inventiva's 10-Year Share Buyback Ratio too high?
Inventiva's current 10-Year Share Buyback Ratio is -25.30. Based on the distribution chart, Inventiva ranks #479 out of 667 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Inventiva has a GF Score™ of 35/100, reflecting its overall financial health beyond just this single metric.
How does Inventiva's 10-Year Share Buyback Ratio compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Inventiva ranks #479 out of 667 companies for 10-Year Share Buyback Ratio. This places Inventiva in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 10-Year Share Buyback Ratio for a Biotechnology company?
A good 10-Year Share Buyback Ratio depends on the Biotechnology industry context. However, 10-Year Share Buyback Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 10-Year Share Buyback Ratio mean?
A high 10-Year Share Buyback Ratio can signal that a stock is expensive relative to its fundamentals. The 10-Year Share Buyback Ratio measures the average annual proportion of a company's outstanding shares repurchased over the past ten years. It is calculated as the annualized percentage change in shares outstanding from ten years ago to the current year. View historical data for Inventiva and its competitors. Inventiva's current 10-Year Share Buyback Ratio is -25.30. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Inventiva stock overvalued right now?
Inventiva (IVEVF) has a current 10-Year Share Buyback Ratio of -25.30. The stock's GF Value™ is $0.21, compared to a current price of $3.59 — trading 1609.5% above its estimated fair value. The current 10-Year Share Buyback Ratio is -25.30. Inventiva's overall GF Score™ is 35/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 10-Year Share Buyback Ratio calculated?
10-Year Share Buyback Ratio is calculated from a company's financial statements. For Inventiva (IVEVF), the current 10-Year Share Buyback Ratio is -25.30 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Inventiva (IVEVF) Overvalued in 2026?

Based on GuruFocus' analysis, Inventiva stock appears to be overvalued. The current stock price of $3.59 is trading 1609.5% above its estimated GF Value™ of $0.21.

Key valuation signals for IVEVF:

  • 10-Year Share Buyback Ratio: -25.30
  • GF Value™: $0.21 vs. price of $3.59 (1609.5% above fair value)
  • GF Score™: 35/100 with 7 warning signs

No single metric tells the full story. See the IVEVF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Inventiva Business Description

Address 50 rue de Dijon, Daix, FRA, 21121
Inventiva SA is a France-based clinical-stage biopharmaceutical company focused on the development of oral small-molecule therapies for the treatment of MASH. The wholly-owned research and development facility and a team with expertise and experience in the development of compounds that target nuclear receptors, transcription factors and epigenetic modulation. Leveraging the expertise, the company is also advancing lanifibranor for the treatment of MASH and has a pipeline of earlier-stage therapeutic programs in oncology. It operates in the segment of Service delivery and clinical stage research, notably into therapies in the areas of oncology, fibrosis, and rare diseases. All the company's operations are in France.
35GF Score

Get the complete analysis for IVEVF

10-Year Share Buyback Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$3.59
Price
$0.21
GF Value